David R. Martinez
A5014451298- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- HIV Research and Treatment
- Mosquito-borne diseases and control
- Viral Infections and Immunology Research
- vaccines and immunoinformatics approaches
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Viral Infections and Vectors
- Virus-based gene therapy research
- Virology and Viral Diseases
- Vaccine Coverage and Hesitancy
- Influenza Virus Research Studies
- COVID-19 Impact on Reproduction
- Long-Term Effects of COVID-19
- HIV/AIDS Research and Interventions
- Viral Infections and Outbreaks Research
- interferon and immune responses
- Blood Coagulation and Thrombosis Mechanisms
- Blood groups and transfusion
- Insect symbiosis and bacterial influences
Universidad del Rosario
2020-2025
Yale University
2023-2024
University of North Carolina at Chapel Hill
2020-2023
IQE (United Kingdom)
2023
Biomedical Research Institute
2023
Texas Biomedical Research Institute
2023
Icahn School of Medicine at Mount Sinai
2023
Baxter (United States)
2023
Institute of Infection and Immunity
2023
Universidad Cooperativa de Colombia
2023
The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome 2 (SARS-CoV-2), a major threat to global health1 and the medical countermeasures available so far are limited2,3. Moreover, we currently lack thorough understanding mechanisms humoral immunity SARS-CoV-24. Here analyse large panel human monoclonal antibodies that target spike (S) glycoprotein5, identify several exhibit potent neutralizing activity fully block receptor-binding...
The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) has made the development of a vaccine top biomedical priority. In this study, we developed series DNA candidates expressing different forms SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals humoral cellular immune responses, including neutralizing antibody titers at levels comparable to those found convalescent humans macaques infected...
Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important evaluate nonhuman primates. Nonhuman primates received 10 or 100 μg mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein SARS-CoV-2, no vaccine. Antibody T-cell responses were assessed before upper- lower-airway challenge with SARS-CoV-2. Active genomes...
An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global disease 2019 (COVID-19) pandemic. A key unanswered question whether infection with SARS-CoV-2 results in against reexposure. We developed a rhesus macaque model observed that macaques had high viral loads upper lower tract, humoral cellular immune responses, pathologic evidence pneumonia. After initial...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first emerged in late 2019 is responsible for a pandemic of illness. People infected with this highly contagious virus can present clinically inapparent, mild, or disease. Currently, the infection individuals and at population level being monitored by PCR testing symptomatic patients presence viral RNA. There an urgent need SARS-CoV-2 serologic tests to identify all individuals, irrespective clinical symptoms, conduct...
Coronaviruses are prone to transmission new host species, as recently demonstrated by the spread humans of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causative agent disease 2019 (COVID-19) pandemic1. Small animal models that recapitulate SARS-CoV-2 needed urgently for rapid evaluation medical countermeasures2,3. cannot infect wild-type laboratory mice owing inefficient interactions between viral spike protein and mouse orthologue human receptor, angiotensin-converting...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of novel viral disease COVID-19. With no approved therapies, this pandemic illustrates urgent need for broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remdesivir (RDV) potently inhibits replication in human lung cells primary airway epithelial cultures (EC50 = 0.01 μM). Weaker activity observed Vero E6 1.65 μM) because their low capacity to metabolize RDV....
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies key class of therapeutics that may bridge widespread vaccination campaigns offer treatment solution in populations less responsive to vaccination. Here, we report high-throughput microfluidic screening antigen-specific B cells led the identification LY-CoV555 (also known as bamlanivimab), potent anti-spike...
SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million infections and 1 deaths since its emergence in December 2019. There are few therapeutic options no approved vaccines. Here, we examine properties highly potent human monoclonal antibodies (hu-mAbs) a Syrian hamster model SARS-CoV-2 mouse-adapted infection (SARS-CoV-2 MA). Antibody combinations were effective prevention therapy when administered early. However, vitro antibody neutralization potency did not...
Abstract The Ad26.COV2.S vaccine 1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including the B.1.351 variant that is partially resistant to neutralizing antibodies 1 . However, immunogenicity of this in humans SARS-CoV-2 variants concern remains unclear. Here we report humoral and cellular immune responses from 20 vaccinated individuals COV1001 phase I–IIa trial 2 original strain WA1/2020 as well B.1.1.7, CAL.20C, P.1 concern. induced median pseudovirus antibody titres...
Defenses against SARS-CoV-2 variants Our key defense the COVID-19 pandemic is neutralizing antibodies virus elicited by natural infection or vaccination. Recent emerging viral have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four from early-outbreak convalescent donors that are potent 23 variants, including concern, and characterized binding spike protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan examined...
Abstract Pediatric vaccines have significantly reduced infectious disease–related infant mortality, but as protective immunity often requires several vaccine doses, maternally acquired Abs are critical to protect infants during the first months of life. Consequently, immunization pregnant women is an important strategy not only mothers from infection, also provide young infants. Nevertheless, maternal can negatively impact early life immunity. In fact, interfere with development immune...
A broad defense against SARS-like viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third that has emerged as a serious human pathogen in past 20 years. Treatment strategies are broadly protective current and future coronaviruses needed. Martinez et al . take on this challenge by developing vaccines based chimeras of viral spike protein. The messenger RNA encode proteins composed domain modules from epidemic pandemic coronaviruses, well bat with potential to cross...
SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification LY-CoV555, potent anti-spike neutralizing antibody from convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding receptor-binding domain, ACE2 inhibition, activity. In rhesus macaque challenge model, prophylaxis doses as low 2.5...
Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against novel pandemic coronaviruses and more effectively respond SARS-CoV-2 variants. The emergence of Omicron subvariants illustrates limitations solely targeting receptor-binding domain (RBD) spike (S) protein. Here, we isolated a large panel (bnAbs) from recovered-vaccinated donors, which targets conserved S2 region in betacoronavirus fusion machinery. Select bnAbs showed broad vivo...
Severe acute respiratory syndrome coronaviruses 1 (SARS-CoV) and 2 (SARS-CoV-2), including SARS-CoV-2 variants of concern, can cause deadly infections. The mortality associated with sarbecovirus infection underscores the importance developing broadly effective countermeasures against them, which could be key in prevention mitigation current future zoonotic events. Here, we demonstrate neutralization SARS-CoV; bat WIV-1 RsSHC014; D614G, B.1.1.7, B.1.351, P.1, B.1.429, B.1.526, B.1.617.1,...
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial humans 1 . CV2CoV is second-generation containing non-modified nucleosides but with optimized non-coding regions and enhanced antigen expression. Here we report the results of head-to-head comparison immunogenicity protective non-human primates. We immunized 18 cynomolgus macaques two doses 12 μg lipid nanoparticle-formulated or...